Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis

• Published in: The Journal of surgical research Vol. 61; no. 2; pp. 348 - 354
• Main Authors: DUNNE, J. R, DUNKIN, B. J, NELSON, S, WHITE, J. C
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier 01.03.1996
• Subjects: Animals; Biological and medical sciences; Escherichia coli Infections - blood; Escherichia coli Infections - mortality; Escherichia coli Infections - therapy; Granulocyte Colony-Stimulating Factor - therapeutic use; Immunomodulators; Leukocyte Count - drug effects; Male; Medical sciences; Neutrophils - drug effects; Neutrophils - physiology; Peritonitis - blood; Peritonitis - mortality; Peritonitis - therapy; Pharmacology. Drug treatments; Rats; Rats, Sprague-Dawley; Immune response; Rat; Septicemia; Escherichia coli; Cytokine; Rodentia; Infection; Vertebrata; Chemotherapy; Granulocyte colony stimulating factor; Mammalia; Polypeptide; Abdominal disease; Animal; Bacteriosis; Bacteria; Pretreatment; Mechanism of action; Pellet(dosage form); Peritonitis; Enterobacteriaceae
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1006/jsre.1996.0128

Despite improved antimicrobials and advances in caring for critically ill patients, mortality from sepsis is still unacceptably high. Upregulation of the cellular immune system is one strategy for decreasing mortality in subjects with severe sepsis, which appears to be promising. Granulocyte colony stimulating factor (G-CSF) has been used successfully to decrease mortality in neutropenic subjects with sepsis. In this study, we have investigated whether pretreatment with G-CSF decreases mortality in non-neutropenic rodents with lethal Escherichia coli peritonitis. We implanted agar pellets impregnated with 5 x 10(8) cfu of Escherichia coli into the peritoneal cavities of rats pretreated with 50 micrograms/kg of G-CSF or an equal volume of 5% dextrose in water (D5W). Survival of these animals increased from 38 to 78% with G-CSF pretreatment. We also demonstrated an 11-fold increase in the number of polymorphonuclear leukocytes (PMNs) in animals treated with G-CSF. This increase in cells was seen initially only in the peripheral circulation. Twenty-four hours after induction of peritonitis, however, there was a three-fold greater increase in number of PMNs recovered from the peritoneal cavities of animals pretreated with G-CSF as compared to those treated with D5W. PMNs recovered from the peritoneal cavities of these animals had significantly elevated bactericidal activity (74% killing vs 53% killing) as compared to those cells recovered from the peritoneal cavities of control animals. These results indicate that G-CSF pretreatment improves survival of non-neutropenic animals with lethal Escherichia coli peritonitis by enhancing the cellular arm of the immune response.